Technology Commercialization Office

Showing 5 result(s) for "Oncology"



A combination-therapy that has the potential to overcome and/or prevent the commonly observed acquisition of sorafenib resistance, which is associated with treatment failure in patients with hepatocellular carcinoma.

An efficient delivery vehicle for therapeutic oligonucleotides with high efficiency.

Self-assembling, highly stable RNA cages amenable to custom functionalization and cargo delivery

Parthenolide analogues derived from plants could be effective in treating leukemia or supplementing other treatments.

Nucleolin (NCL) is up-regulated in cancer cells, and modulates pro-tumorigenic pathways and chemoresistance. This anti-NCL agent binds and blocks NCL signaling, and may be optimized as cancer therapeutic and diagnostic tool.